Advertisement

Rectal Cancer Radiotherapy and Older Patients: Evidence-Based or Opinion-Based Treatment?

  • Rob Glynne-JonesEmail author
  • Kannon Nathan
Chapter

Abstract

Colorectal cancer is the most common malignancy in patients aged 75 years or older, and the incidence is likely to rise further as the population ages and survival increases. Sound data on the adherence to guidelines for the elderly and the uptake of treatment in the elderly is limited. However, the evidence available suggests that clinical attitudes observed regarding age and cancer treatment are consistent, such that older people with colorectal cancer tend to be offered less intensive treatment or no treatment. So how do doctors balance chronological age, comorbidity and social isolation, and other influences on their clinical decision making?

Keywords

Colorectal cancer Chemotherapy Radiotherapy Toxicity Compliance Decision making 

References

  1. 1.
    Boyle P, Langman JS. ABC of colorectal cancer: epidemiology. BMJ. 2000;321(7264):805–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Boyle P, Leon ME. Epidemiology of colorectal cancer. Br Med Bull. 2002;64:1–25. Review.PubMedCrossRefGoogle Scholar
  3. 3.
    Martijn H, Vulto JC. Should radiotherapy be avoided or delivered differently in elderly patients with rectal cancer? Eur J Cancer. 2007;43(15):2301–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Papamichael D, Audisio R, Horiot JC, et al. Treatment of the elderly colorectal cancerpatient: SIOG expert recommendations. Ann Oncol. 2009;20(1):5–16.PubMedCrossRefGoogle Scholar
  5. 5.
    Lichtman SM. Management of advanced colorectal cancer in older patients. Oncology (Williston Park). 2005;19(5):597–602.Google Scholar
  6. 6.
    Endreseth BH, Romundstad P, Myrvold HE, Bjerkeset T, Wibe A, Norwegian Rectal Cancer Group. Rectal cancer treatment of the elderly. Colorectal Dis. 2006;8(6):471–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Devon KM, Vergara-Fernandez O, Victor JC, McLeod RS. Colorectal cancer surgery in elderly patients: presentation, treatment, and outcomes. Dis Colon Rectum. 2009;52(7):1272–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Shahir MA, Lemmens VE, van de Poll-Franse LV, Voogd AC, Martijn H, Janssen-Heijnen ML. Elderly patients with rectal cancer have a higher risk of treatment-related complications and a poorer prognosis than younger patients: a population-based study. Eur J Cancer. 2006;42(17):3015–21.PubMedCrossRefGoogle Scholar
  9. 9.
    Chang GJ, Skibber JM, Feig BW, Rodriguez-Bigas M. Are we undertreating rectal cancer in the elderly? An epidemiologic study. Ann Surg. 2007;246(2):215–21.PubMedCrossRefGoogle Scholar
  10. 10.
    Peeters KC, Marijnen CA, Nagtegaal ID, Kranenbarg EK, Putter H, Wiggers T, Dutch Colorectal Cancer Group, et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg. 2007;246(5):693–701.PubMedCrossRefGoogle Scholar
  11. 11.
    Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomized trial. Lancet. 2009;373(9666):811–20.PubMedCrossRefGoogle Scholar
  12. 12.
    van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T, Dutch Colorectal Cancer Group, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomized controlled TME trial. Lancet Oncol. 2011;12(6):575–82.PubMedCrossRefGoogle Scholar
  13. 13.
    Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, German Rectal Cancer Study Group, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–40.PubMedCrossRefGoogle Scholar
  14. 14.
    Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al. Chemoradiotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114–23.PubMedCrossRefGoogle Scholar
  15. 15.
    Gerard JP, Conroy T, Bonnetain F, Bouche O, Chapet O, Closon-Dejardin MT, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-T4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24:4620–5.PubMedCrossRefGoogle Scholar
  16. 16.
    Roh MS, Colangelo LH, O’Connell MJ, Yothers G, Deutsch M, Alegra CJ, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R03. J Clin Oncol. 2009;27:5124–30.PubMedCrossRefGoogle Scholar
  17. 17.
    Paun BC, Cassie S, MacLean AR, Dixon E, Buie WD. Postoperative complications following surgery for rectal cancer. Ann Surg. 2010;251(5):807–18.PubMedCrossRefGoogle Scholar
  18. 18.
    Borowski DW, Bradburn DM, Mills SJ, Bharathan B, Wilson RG, Ratcliffe AA, Kelly SB. Volume-outcome analysis of colorectal cancer-related outcomes. Br J Surg. 2010;97:1416–30.PubMedCrossRefGoogle Scholar
  19. 19.
    Rutten HJ, den Dulk M, Lemmens VE, van de Velde CJ, Marijnen CA. Controversies of total mesorectal excision for rectal cancer in elderly patients. Lancet Oncol. 2008;9(5):494–501.PubMedCrossRefGoogle Scholar
  20. 20.
    Gervaz PA, Wexner SD, Pemberton JH. Pelvic radiation and anorectal function: introducing the concept of sphincter-preserving radiation therapy. J Am Coll Surg. 2002;195:387–94.PubMedCrossRefGoogle Scholar
  21. 21.
    Bujko K, Nowacki MP, Nasierowska-Guttmejer A, for the Polish Colorectal Study Group. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93(10):1215–23.PubMedCrossRefGoogle Scholar
  22. 22.
    Ring A, Sestak I, Baum M, Howell A, Buzdar A, Dowsett M, Forbes JF, Cuzick J. Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen alone or in combination trial. J Clin Oncol. 2011;29(32):4266–72.PubMedCrossRefGoogle Scholar
  23. 23.
    Sanoff HK, Goldberg RM. Colorectal cancer treatment in older patients. Gastrointest Cancer Res. 2007;1(6):248–53.PubMedGoogle Scholar
  24. 24.
    Faivre-Finn C, Benhamiche AM, Maingon P, et al. Changes in the practice of adjuvant radiotherapy in resectable rectal cancer within a French well-defined population. Radiother Oncol. 2000;57:137–42.PubMedCrossRefGoogle Scholar
  25. 25.
    Ayanian JZ, Zaslavsky AM, Fuchs CS, et al. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol. 2003;21:1293–300.PubMedCrossRefGoogle Scholar
  26. 26.
    Jung B, Påhlman L, Johansson R, Nilsson E. Rectal cancer treatment and outcome in the elderly: an audit based on the Swedish Rectal Cancer Registry 1995–2004. BMC Cancer. 2009;9:68.PubMedCrossRefGoogle Scholar
  27. 27.
    Gagliardi G, Pucciarelli S, Asteria CR, et al. A nationwide audit of the use of radiotherapy for rectal cancer in Italy. Tech Coloproctol. 2010;14(3):229–35.PubMedCrossRefGoogle Scholar
  28. 28.
    Aparicio T, Navazesh A, Boutron I, et al. Half of elderly patients routinely treated for colorectal cancer receive a sub-standard treatment. Crit Rev Oncol Hematol. 2009;71(3):249–57.PubMedCrossRefGoogle Scholar
  29. 29.
    Quipourt V, Jooste V, Cottet V, Faivre J, Bouvier AM. Comorbidities alone do not explain the undertreatment of colorectal cancer in older adults: a French population-based study. J Am Geriatr Soc. 2011;59(4):694–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Holm T, Singnomklao T, Rutqvist LE, Cedermark B. Adjuvant preoperative radiotherapy in patients with rectal carcinoma. Adverse effects during long term follow-up of two randomized trials. Cancer. 1996;78(5):968–76.PubMedCrossRefGoogle Scholar
  31. 31.
    Pignon T, Horiot JC, Bolla M, van Poppel H, Bartelink H, Roelofsen F, Pene F, Gerard A, Einhorn N, Nguyen TD, Vanglabbeke M, Scalliet P. Age is not a limiting factor for radical radiotherapy in pelvic malignancies. Radiother Oncol. 1997;42(2):107–20.PubMedCrossRefGoogle Scholar
  32. 32.
    Kalata P, Martus P, Zettl H, Rödel C, Hohenberger W, Raab R, Becker H, Liersch T, Wittekind C, Sauer R, Fietkau R, German Rectal Cancer Study Group. Differences between clinical trial participants and patients in a population-based registry: the German Rectal Cancer Study vs. the Rostock Cancer Registry. Dis Colon Rectum. 2009;52(3):425–37.PubMedCrossRefGoogle Scholar
  33. 33.
    Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341:2061–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age based disparities. JAMA. 2004;291:2720–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001;345:1091–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Goldberg RM, Tabah-Fisch I, Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol. 2006;24:4085–91.PubMedCrossRefGoogle Scholar
  37. 37.
    Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomized trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol. 2004;72:15–24.PubMedCrossRefGoogle Scholar
  38. 38.
    Swedish Rectal Cancer Trial: Initial report from a Swedish multicentre study examining the role of preoperative irradiation in the treatment of patients with resectable rectal carcinoma. Br J Surg. 1993; 80: 1333–6.Google Scholar
  39. 39.
    Ngan S, Fisher R, Goldstein D, et al. TROG, AGITG, CSSANZ, and RACS. A randomized trial comparing local recurrence (LR) rates between short-course (SC) and long-course (LC) preoperative radiotherapy (RT) for clinical T3 rectal cancer: an intergroup trial (TROG, AGITG, CSSANZ, RACS). J Clin Oncol. 2010;28(15 Suppl):abstract 3509.Google Scholar
  40. 40.
    Petersson D, Cedermark B, Holm T, Radu C, Påhlman L, Glimelius B, Martling A. Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer. Br J Surg. 2010;97(4):580–7.CrossRefGoogle Scholar
  41. 41.
    Radu C, Berglund A, Pahlman L, Glimelius B. Short-course preoperative radiotherapy with delayed surgery in rectal cancer – a retrospective study. Radiother Oncol. 2008;87(3):343–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Hatfield P, Hingorani M, Radhakrishna G, Cooper R, Melcher A, Crellin A, Kwok-Williams M, Sebag-Montefiore D. Short-course radiotherapy, with elective delay prior to surgery, in patients with unresectable rectal cancer who have poor performance status or significant co-morbidity. Radiother Oncol. 2009;92(2):210–4.PubMedCrossRefGoogle Scholar
  43. 43.
    Paszat LF, Brundage MD, Groome PA, Schulze K, Mackillop WJ. A population-based study of rectal cancer: permanent colostomy as an outcome. Int J Radiat Oncol Biol Phys. 1999;45(5):1185–91.PubMedCrossRefGoogle Scholar
  44. 44.
    Schrag D, Gelfand SE, Bach PB, Guillem J, Minsky BD, Begg CB. Who gets adjuvant treatment for stage II and III rectal cancer? Insight from surveillance, epidemiology, and end results—Medicare. J Clin Oncol. 2001;19(17):3712–8.PubMedGoogle Scholar
  45. 45.
    Schroen AT, Cress RD. Use of surgical procedures and adjuvant therapy in rectal cancer treatment: a population-based study. Ann Surg. 2001;234(5):641–51.PubMedCrossRefGoogle Scholar
  46. 46.
    Neugut AI, Fleischauer AT, Sundararajan V, et al. Use of adjuvant chemotherapy and radiation therapy for rectal canceramong the elderly: a population-based study. J Clin Oncol. 2002;20:2643–50.PubMedCrossRefGoogle Scholar
  47. 47.
    Dharma-Wardene MW, de Gara C, Au HJ, Hanson J, Hatcher J. Ageism in rectal carcinoma? Treatment and outcome variations. Int J Gastrointest Cancer. 2002;32(2–3):129–38.PubMedCrossRefGoogle Scholar
  48. 48.
    Phelip JM, Milan C, Herbert C, Grosclaude P, Arveux P, Raverdy N, Daures JP, Faivre J. Evaluation of the management of rectal cancers before and after the consensus conference in France. Eur J Gastroenterol Hepatol. 2004;16(10):1003–9.PubMedCrossRefGoogle Scholar
  49. 49.
    Baxter NN, Rothenberger DA, Morris AM, Bullard KM. Adjuvant radiation for rectal cancer: do we measure up to the standard of care? An epidemiologic analysis of trends over 25 years in the United States. Dis Colon Rectum. 2005;48(1):9–15.PubMedCrossRefGoogle Scholar
  50. 50.
    Vulto AJ, Lemmens VE, Louwman MW, et al. The influence of age and co-morbidity on receiving radiotherapy as part of primary treatment for cancer in south Netherlands, 1995–2002. Cancer. 2006;106:2734–42.PubMedCrossRefGoogle Scholar
  51. 51.
    Larsen SG, Wiig JN, Tretli S, Giercksky KE. Surgery and pre-operative irradiation for locally advanced or recurrent rectal cancer in patients over 75 years of age. Colorectal Dis. 2006;8(3):177–85.PubMedCrossRefGoogle Scholar
  52. 52.
    Wolff HA, Conradi LC, Schirmer M, Beissbarth T, Sprenger T, Rave-Fränk M, Hennies S, Hess CF, Becker H, Christiansen H, Liersch T. Gender-specific acute organ toxicity during intensified preoperative radiochemotherapy for rectal cancer. Oncologist. 2011;16(5):621–31.PubMedCrossRefGoogle Scholar
  53. 53.
    Lorchel F, Peignaux K, Créhange G, Bosset M, Puyraveau M, Mercier M, Bosset JF, Maingon P. Preoperative radiotherapy in elderly patients with rectal cancer. Gastroenterol Clin Biol. 2007;31(4):436–41.PubMedCrossRefGoogle Scholar
  54. 54.
    Pasetto LM, Basso U, Friso ML, et al. Determining therapeutic approaches in the elderly with rectal cancer. Drugs Aging. 2007;24(9):781–90.PubMedCrossRefGoogle Scholar
  55. 55.
    Fiorica F, Cartei F, Carau B, Berretta S, Spartà D, Tirelli U, Santangelo A, Maugeri D, Luca S, Leotta C, Sorace R, Berretta M. Adjuvant radiotherapy on older and oldest elderly rectal cancer patients. Arch Gerontol Geriatr. 2009;49(1):54–9.PubMedCrossRefGoogle Scholar
  56. 56.
    Margalit DN, Mamom HJ, Ancukiewicz M, et al. Tolerability of combined modality therapy for rectal cancer in elderly patients aged 75 years and older. Int J Radiat Oncol Biol Phys. 2011;81(5):e735–41.PubMedCrossRefGoogle Scholar
  57. 57.
    Seymour MT, Thompson LC, Wasan HS, Middleton G, Brewster AE, Shepherd SF, O’Mahony MS, Maughan TS, Parmar M, Langley RE, FOCUS2 Investigators; National Cancer Research Institute Colorectal Cancer Clinical Studies Group. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomized factorial trial. Lancet. 2011;377(9779):1749–59.PubMedCrossRefGoogle Scholar
  58. 58.
    Peeters KC, van de Velde CJ, Leer JW, Martijn H, Junggeburt JM, Kranenbarg EK, Steup WH, Wiggers T, Rutten HJ, Marijnen CA. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients–a Dutch colorectal cancer group study. J Clin Oncol. 2005;23(25):6199–206.PubMedCrossRefGoogle Scholar
  59. 59.
    Bacon C, Giovannucci E, Testa M, et al. The association of treatment-related symptoms with quality-of-life outcomes for localized prostate carcinoma patients. Cancer. 2002;94:862–71.PubMedCrossRefGoogle Scholar
  60. 60.
    Andreyev HJ. Gastrointestinal problems following pelvic radiotherapy: the past, the present and the future. Clin Oncol (R Coll Radiol). 2007;19:790–9.CrossRefGoogle Scholar
  61. 61.
    Pucciarelli S, Gagliardi G, Maretto I, et al. Long-term oncologic results and complications after preoperative chemoradiotherapy for rectal cancer: a single-institution experience after a median follow-up of 95 months. Ann Surg Oncol. 2009;16(4):893–9.PubMedCrossRefGoogle Scholar
  62. 62.
    Lange MM, van de Velde CJ. Faecal and urinary incontinence after multimodality treatment of rectal cancer. PLoS Med. 2008;5(10):e202.PubMedCrossRefGoogle Scholar
  63. 63.
    Lönn S, Gilbert ES, Ron E, et al. Comparison of second cancer risks from brachytherapy and external beam therapy after uterine corpus cancer. Cancer Epidemiol Biomarkers Prev. 2010;19(2):464–74.PubMedCrossRefGoogle Scholar
  64. 64.
    Bouvier AM, Jooste V, Bonnetain F, et al. Adjuvant treatments do not alter the quality of life in elderly patients with colorectal cancer: a population-based study. Cancer. 2008;113(4):879–86.PubMedCrossRefGoogle Scholar
  65. 65.
    Boige V, Mendiboure J, Pignon JP, et al. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000–05. J Clin Oncol. 2010;28:2556–64.PubMedCrossRefGoogle Scholar
  66. 66.
    Agostini M, Pasetto LM, Pucciarelli S, Terrazzino S, Ambrosi A, Bedin C, Galdi F, Friso ML, Mescoli C, Urso E, Leon A, Lise M, Nitti D. Glutathione S-transferase P1 Ile105Val polymorphism is associated with haematological toxicity in elderly rectal cancer patients receiving preoperative chemoradiotherapy. Drugs Aging. 2008;25(6):531–9.PubMedCrossRefGoogle Scholar
  67. 67.
    Vuong T, Belliveau PJ, Michel RP, Moftah BA, Parent J, Trudel JL, Reinhold C, Souhami L. Conformal preoperative endorectal brachytherapy treatment for locally advanced rectal cancer: early results of a phase I/II study. Dis Colon Rectum. 2002;45:1486–93.PubMedCrossRefGoogle Scholar
  68. 68.
    Kaufman N, Nori D, Shank B, Linares L, Harrison L, Fass D, Enker W. Remote afterloading intraluminal brachytherapy in the treatment of rectal, rectosigmoid, and anal cancer: a feasibility study. Int J Radiat Oncol Biol Phys. 1989;17:663–8.PubMedCrossRefGoogle Scholar
  69. 69.
    Jakobsen A, Mortensen JP, Bisgaard C, Lindebjerg J, Hansen JW, Rafaelsen SR. Preoperative chemoradiation of locally advanced T3 rectal cancer combined with an endorectal boost. Int J Radiat Oncol Biol Phys. 2006;64:461–5.PubMedCrossRefGoogle Scholar
  70. 70.
    Corner C, Bryant L, Chapman C, Glynne-Jones R, Hoskin PJ. High-dose-rate afterloading intraluminal brachytherapy for advanced inoperable rectal carcinoma. Brachytherapy. 2010;9:66–70.PubMedCrossRefGoogle Scholar
  71. 71.
    Tunio MA, Rafi M, Hashmi A, et al. High-dose-rate intraluminal brachytherapy during preoperative chemoradiation for locally advanced rectal cancers. World J Gastroenterol. 2010;16(35):4436–42.PubMedCrossRefGoogle Scholar
  72. 72.
    Cesari M, et al. Fraility syndrome and skeletal muscle: results from the Invecchiare in Chianti study. Am J Clin Nutr. 2006;83:1142–8.PubMedGoogle Scholar
  73. 73.
    Charlson M, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.PubMedCrossRefGoogle Scholar
  74. 74.
    Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol. 2007;25:1824–31.PubMedCrossRefGoogle Scholar
  75. 75.
    Extermann M, Overcash J, Lyman G, et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998;16:1582–7.PubMedGoogle Scholar
  76. 76.
    Chen H, Overcash J, Extermann M, et al. Comprehensive geriatric assessment in elderly cancer patients: impact on overall survival and progression free survival. Poster P76. In: American Geriatric Society meeting, Philadelphia, 19–23 May 1999.Google Scholar
  77. 77.
    Saliba D, et al. The vulnerable elders survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc. 2001;49:1691–9.PubMedCrossRefGoogle Scholar
  78. 78.
    Rodin MB, Mohile SG. A practical approach to geriatric assessment in oncology. J Clin Oncol. 2007;25:1936–44.PubMedCrossRefGoogle Scholar
  79. 79.
    Mohile SG, et al. A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation. Cancer. 2007;109:802–10.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  1. 1.Clinical OncologyMount Vernon Cancer CentreNorthwood, MiddlesexUK
  2. 2.Clinical OncologyMount Vernon Cancer CentreMiddlesexUK

Personalised recommendations